Pyxis Oncology (NASDAQ:PYXS - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter.
Pyxis Oncology Price Performance
Shares of NASDAQ PYXS traded up $0.05 during trading hours on Friday, hitting $1.12. 213,068 shares of the company's stock were exchanged, compared to its average volume of 757,059. The company's 50-day moving average price is $1.39 and its 200-day moving average price is $2.47. The stock has a market capitalization of $66.30 million, a price-to-earnings ratio of -1.08 and a beta of 1.12. Pyxis Oncology has a 1-year low of $0.99 and a 1-year high of $6.18.
Institutional Investors Weigh In On Pyxis Oncology
A hedge fund recently raised its stake in Pyxis Oncology stock. Bank of America Corp DE grew its stake in Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 20.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 53,745 shares of the company's stock after purchasing an additional 9,062 shares during the period. Bank of America Corp DE owned approximately 0.09% of Pyxis Oncology worth $84,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 39.09% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have commented on PYXS shares. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price target (down previously from $7.00) on shares of Pyxis Oncology in a report on Friday, December 20th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $8.00 price target (down previously from $10.00) on shares of Pyxis Oncology in a report on Friday, December 20th. Finally, William Blair cut Pyxis Oncology from an "outperform" rating to a "market perform" rating in a report on Thursday, November 21st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $9.20.
View Our Latest Analysis on PYXS
About Pyxis Oncology
(
Get Free Report)
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Further Reading
Before you consider Pyxis Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pyxis Oncology wasn't on the list.
While Pyxis Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
